유럽 ​​간암 진단 시장 – 2030년까지의 산업 동향 및 예측

TOC 요청 TOC 요청 분석가에게 문의 분석가에게 문의 지금 구매 지금 구매 구매하기 전에 문의 구매하기 전에 문의 무료 샘플 보고서 무료 샘플 보고서

유럽 ​​간암 진단 시장 – 2030년까지의 산업 동향 및 예측

  • Medical Devices
  • Published Report
  • Apr 2023
  • Europe
  • 350 Pages
  • 테이블 수: 293
  • 그림 수: 58

Europe Liver Cancer Diagnostics Market

시장 규모 (USD 10억)

연평균 성장률 :  % Diagram

Diagram 예측 기간
2023 –2030
Diagram 시장 규모(기준 연도)
USD 1,593.49 Million
Diagram 시장 규모(예측 연도)
USD 2,533.55 Million
Diagram 연평균 성장률
%
Diagram주요 시장 플레이어
  • Dummy1
  • Dummy2
  • Dummy3
  • Dummy4
  • Dummy5

>유럽 ​​간암 진단 시장, 검사 유형(영상 검사, 생검, 유전체 검사 등), 암 병기(0기, 1기, 2기, 3기, 4기), 암 유형(1차 간암 및 2차 간암), 제품(플랫폼 기반 제품, 기기 기반 제품, 키트 및 시약, 기타 소모품), 기술(형광 현장 교잡법, 차세대 시퀀싱, 형광면역측정법, 비교 유전체 교잡법, 면역조직화학법 등), 응용 분야(선별, 진단 및 예측, 예후, 연구), 성별(여성 및 남성), 최종 사용자(병원, 진단 센터, 암 연구 센터, 학술 기관, 외래 수술 센터 등), 유통 채널(직접 입찰, 소매 판매 등) - 업계 동향 및 2030년까지의 예측.

유럽 ​​간암 진단 시장

유럽 ​​간암 진단 시장 분석 및 통찰력

유럽 ​​간암 진단 시장은 시장 참여자의 증가와 고급 서비스의 가용성으로 인해 예측 연도에 성장할 것으로 예상됩니다. 이와 함께 제조업체는 시장에서 새로운 서비스를 출시하기 위한 R&D 활동에 참여하고 있습니다. 간암에 대한 더 나은 품질의 의료에 대한 수요가 증가하고 예방 건강 검진에 대한 선호도가 높아짐에 따라 시장 성장이 촉진될 것으로 예상됩니다.

유럽 ​​간암 진단 시장유럽 ​​간암 진단 시장

그러나 진단 시술의 높은 비용과 숙련되고 인증된 전문가의 부족은 시장 성장에 어려움을 줄 것으로 예상됩니다.

유럽 ​​간암 진단 시장은 2023년부터 2030년까지의 예측 기간 동안 시장 성장을 이룰 것으로 예상됩니다. Data Bridge Market Research는 시장이 2023년부터 2030년까지의 예측 기간 동안 6.0%의 CAGR로 성장하고 있으며 2022년 1,593.49백만 달러에서 2030년까지 2,533.55백만 달러에 도달할 것으로 예상된다고 분석했습니다.

유럽 ​​간암 진단 시장 보고서는 시장 점유율, 새로운 개발 및 제품 파이프라인 분석, 국내 및 지역 시장 참여자의 영향, 새로운 수익 주머니, 시장 규정의 변화, 제품 승인, 전략적 의사 결정, 제품 출시, 지리적 확장 및 시장의 기술 혁신 측면에서의 분석 기회에 대한 세부 정보를 제공합니다. 분석 및 시장 시나리오를 이해하려면 분석가 브리핑을 위해 당사에 문의하세요. 당사 팀은 원하는 목표를 달성하기 위한 수익 영향 솔루션을 만드는 데 도움을 드립니다. 다양한 지역의 개발도상국에 있는 소매점의 확장성과 사업 확장, 기계 및 의약품의 안전한 유통을 위한 공급업체와의 파트너십은 예측 기간 동안 시장 수요를 촉진한 주요 원동력입니다.

보고서 메트릭

세부

예측 기간

2023년부터 2030년까지

기준 연도

2022

역사적 연도

2021 (2015-2020까지 사용자 정의 가능)

양적 단위

수익 (단위: USD 백만)

다루는 세그먼트

검사 유형(영상 검사, 생검, 유전체 검사 등), 암 병기(0기, 1기, 2기, 3기, 4기), 암 유형(1차 간암 및 2차 간암), 제품(플랫폼 기반 제품, 기기 기반 제품, 키트 및 시약, 기타 소모품), 기술(형광 현장 하이브리다이제이션, 차세대 시퀀싱, 형광면역측정법, 비교 유전체 하이브리다이제이션, 면역조직화학, 기타), 응용 분야(선별, 진단 및 예측, 예후, 연구), 성별(여성 및 남성), 최종 사용자(병원, 진단 센터, 암 연구 센터, 학술 기관, 외래 수술 센터 등), 유통 채널(직접 입찰, 소매 판매, 기타)

적용 국가

독일, 프랑스, ​​영국, 이탈리아, 러시아, 스페인, 네덜란드, 스위스, 노르웨이, 폴란드, 스웨덴, 벨기에, 터키, 덴마크, 핀란드 및 유럽의 나머지 지역

시장 참여자 포함

Siemens Healthcare GmbH(독일), Koninklijke Philips NV(네덜란드), Agilent Technologies, Inc.(미국), Illumina, Inc.(미국), Epigenomics AG(독일), Tebubio, Thermo Fisher Scientific Inc.(미국), QIAGEN(미국), F. Hoffmann-La Roche Ltd(스위스), Fujirebio(일본), Diagnostic Biosystems Inc.(미국), FUJIFILM Corporation(일본), MOLGEN(네덜란드), Sysmex Corporation(일본), Hipro Biotechnology Co., Ltd.(중국), Altogen Biosystems(미국), ABK Biomedical Inc.(캐나다), Diazyme Laboratories, Inc.(미국) 등이 있습니다.

시장 정의

간암 진단은 간암을 탐지하고 진단하는 데 사용되는 다양한 방법과 기술을 말합니다. 여기에는 실험실 검사, 영상 검사 및 신체 검사가 포함될 수 있습니다.

간암 진단 시장에는 진단 실험실, 의료 기기 제조업체, 제약 회사를 포함한 다양한 회사의 광범위한 제품과 서비스가 포함됩니다. 이 시장은 간암 발병률 증가와 정확하고 신뢰할 수 있는 진단 검사에 대한 수요 증가에 의해 주도됩니다.

유럽 ​​간암 진단 시장 동향

운전자

  • 조기 암 발견을 위한 비침습적, 정확하고 신뢰할 수 있는 진단 검사에 대한 충족되지 않은 요구

진단은 또한 기초 연구의 최신 발전을 환자에게 더 나은 임상적 결과로 전환하는 데 점점 더 중요한 도구가 되고 있습니다. 새롭고, 빠르고, 민감하고, 덜 침습적이며, 더 정확한 분자 진단 검사의 개발은 유전체학, 단백체학 및 기타 "오믹스" 기술을 포함하여 당시 가장 흥미로운 과학적 발전 중 일부에 의해 가속화되고 있습니다. 이는 다양한 암을 더 일찍, 더 정확하게 식별하고 치료하는 능력에 상당한 영향을 미칩니다. 각 환자의 고유한 분자 프로필에 따라 약물을 맞춤화함으로써 진단은 의사가 더 잘 교육된 치료 결정을 내리는 데 도움이 됩니다.

따라서 조기 암 발견 수요를 충족하기 위한 비침습적, 정확하고 신뢰할 수 있는 진단 검사에 대한 충족되지 않은 수요가 시장 성장을 촉진할 것으로 예상됩니다.

  • 간암 조기진단 증가

머신 러닝은 복잡한 데이터에서 패턴을 파악하도록 컴퓨터를 훈련시키는 조기 암 진단에 혁명을 일으킬 수 있습니다. 도구에는 일반적인 건강 데이터 평가, 의료 영상, 생검 샘플 및 혈액 검사가 포함되어 조기 진단 및 위험 계층화에 도움이 됩니다. 많은 종양 유형에서 성공적인 치료를 받을 가능성은 조기 암 진단과 함께 증가합니다. 중요한 전략 중 하나는 증상이 없는 위험 환자를 평가하고 증상이 있는 환자에게 신속하고 적절하게 대응하는 것입니다.

따라서 조기 발견으로 치료 옵션, 환자 결과, 생존율이 향상되고 유럽 간암 진단 시장 성장을 촉진할 것으로 예상됩니다.

제지

  • 간암 진단의 장벽과 불량한 예후

암은 선진국과 개발도상국에서 사망의 주요 원인입니다. 암 사망률은 2030년까지 연간 약 1,310만 명으로 증가할 것으로 예상됩니다. 그러나 특정 유형의 암은 조기에 발견하여 적절히 치료하면 치료될 가능성이 높습니다. 암 진단 지연은 진단 경로 전체, 즉 환자, 1차 진료, 2차 진료에서 발생할 수 있습니다. 환자가 의심스러운 암 증상을 인식하고 조치하지 못하면 환자 지연이 발생할 수 있습니다. 초기 암 증상에 대한 대중의 인식이 부족한 것이 지연된 증상 발현의 주된 이유로 간주되며, 특히 증상이 비정형적인 경우 더욱 그렇습니다.

늦은 진단은 종종 이러한 요인에서 비롯되며, 이로 인해 예후가 좋지 않습니다. 따라서 이러한 요인들이 유럽 간암 진단 시장의 성장을 억제할 것으로 예상됩니다.

기회

  • 간암에 대한 인식 증가

간암 인식은 이러한 질병에 대한 지식을 높이고 원인, 예방, 진단, 치료 및 생존에 대한 연구에 주목하게 하는 기회입니다. 목표는 간의 영향을 받은 사람들을 돕고 건강한 습관을 장려하는 것입니다. 원발성 간암은 간에서 발생하는 암의 이름입니다. 간세포암은 성인에서 가장 흔한 원발성 간암(HCC)입니다. 전 세계적으로 암 관련 사망의 세 번째로 흔한 원인은 이 특정 형태의 간암입니다. 미국에서는 매년 약 25,000명의 남성과 11,000명의 여성이 간암 진단을 받고, 이 질병으로 인해 19,000명의 남성과 9,000명의 여성이 사망합니다.

따라서 간암 진단에 대한 정부 주도의 정책은 시장 성장의 기회를 창출할 것으로 기대됩니다.

도전

  • 간암 진단제품 승인에 대한 엄격한 규정

제품 승인 및 시장 상용화에 대한 엄격한 가이드라인은 전 세계 암 진단 제품 제조업체에 큰 장애물로 입증되고 있습니다. 모든 국가는 자체 규정을 가지고 있으며 다른 규제 기관을 고용합니다.

의료 기기 생산 및 마케팅에 참여하는 업체는 엄격한 규정의 결과로 조정해야 합니다. 이는 전 세계의 모든 이해 관계자에게 영향을 미치며, 이는 예측 기간 내내 시장에 도전할 것으로 예상됩니다. 따라서 유럽 간암 진단 시장의 성장을 방해하는 도전으로 작용할 것으로 예상됩니다.

최근 개발

  • 2022년 12월, FUJIFILM Holdings America Corporation은 Inspirata, Inc.와 인수 계약을 맺고 디지털 병리학 사업을 인수하여 강력한 엔터프라이즈 이미징 서비스를 확장한다고 발표했습니다. 이를 통해 병리학 이미지와 데이터를 의료 기관의 전자 건강 기록 시스템에 통합하여 종양 환자의 치료 제공을 간소화할 수 있습니다.

유럽 ​​간암 진단 시장 범위

유럽 ​​간암 진단 시장은 검사 유형, 암 유형, 암 단계, 제품, 응용 프로그램, 기술, 성별, 최종 사용자 및 유통 채널의 9가지 주요 부문으로 분류됩니다.

테스트 유형별

  • 영상 테스트
  • 생검
  • 게놈 검사
  • 기타

암 단계별

  • 0단계
  • 1단계
  • 2단계
  • 3단계
  • 4단계

암 유형별

  • 원발성 간암
  • 2차 간암

제품별로

  • 플랫폼 기반 제품
  • 계측 기반 제품
  • 키트 및 시약
  • 기타 소모품

기술로

  • 형광 현장 하이브리디제이션
  • 차세대 시퀀싱
  • 불소면역측정법
  • 비교 게놈 교잡화
  • 면역조직화학
  • 기타

응용 프로그램으로

  • 상영
  • 진단 및 예측
  • 전조
  • 연구

성별로

  • 여성
  • 남성

최종 사용자별

  • 병원
  • 암 연구 센터
  • 학술 기관
  • 진단 센터
  • 외래 수술 센터
  • 기타

유통 채널별

  • 직접 입찰
  • 소매 판매
  • 기타

간암 진단 시장

유럽 ​​간암 진단 시장 지역 분석/통찰력

유럽 ​​간암 진단 시장은 검사 유형, 암 단계, 암 유형, 제품, 응용 프로그램, 기술, 성별, 최종 사용자 및 유통 채널을 기준으로 9개의 주요 세그먼트로 구분됩니다.

이 시장 보고서에서 다루는 국가는 독일, 프랑스, ​​영국, 이탈리아, 러시아, 스페인, 네덜란드, 스위스, 노르웨이, 벨기에, 터키 및 기타 유럽 국가입니다.

독일은 간암 진단 제품 생산 증가, 신흥 시장의 수요 증가, 의료 산업 확대로 인해 우위를 점하고 있습니다.

보고서의 국가 섹션은 또한 개별 시장 영향 요인과 국내 시장의 현재 및 미래 트렌드에 영향을 미치는 규제 변화를 제공합니다. 신규 판매, 교체 판매, 국가 인구 통계, 규제 조치 및 수출입 관세와 같은 데이터 포인트는 개별 국가의 시장 시나리오를 예측하는 데 사용되는 주요 포인터 중 일부입니다. 또한 유럽 브랜드의 존재 및 가용성과 지역 및 국내 브랜드와의 대규모 또는 희소한 경쟁으로 인해 직면한 과제, 판매 채널의 영향이 국가 데이터에 대한 예측 분석을 제공하는 동안 고려됩니다.

경쟁 환경 및 유럽 간암 진단 시장 점유율 분석

유럽 ​​간암 진단 시장 경쟁 구도는 경쟁자별 세부 정보를 제공합니다. 포함된 세부 정보에는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, R&D 투자, 새로운 시장 이니셔티브, 생산 현장 및 시설, 회사의 강점과 약점, 제품 출시, 제품 승인, 제품 폭 및 호흡, 응용 프로그램 우세 및 기술 수명선 곡선이 있습니다. 위에 제공된 데이터 포인트는 유럽 간암 진단 시장에 대한 회사의 초점과만 관련이 있습니다.

유럽 ​​간암 진단 시장의 주요 기업으로는 Siemens Healthcare GmbH(독일), Koninklijke Philips NV(네덜란드), Agilent Technologies, Inc.(미국), Illumina, Inc.(미국), Epigenomics AG(독일), Tebubio, Thermo Fisher Scientific Inc.(미국), QIAGEN(미국), F. Hoffmann-La Roche Ltd(스위스), Fujirebio(일본), Diagnostic Biosystems Inc.(미국), FUJIFILM Corporation(일본), MOLGEN(네덜란드), Sysmex Corporation(일본), Hipro Biotechnology Co., Ltd.(중국), Altogen Biosystems(미국), ABK Biomedical Inc.(캐나다), Diazyme Laboratories, Inc.(미국) 등이 있습니다.


SKU-

세계 최초의 시장 정보 클라우드 보고서에 온라인으로 접속하세요

  • 대화형 데이터 분석 대시보드
  • 높은 성장 잠재력 기회를 위한 회사 분석 대시보드
  • 사용자 정의 및 질의를 위한 리서치 분석가 액세스
  • 대화형 대시보드를 통한 경쟁자 분석
  • 최신 뉴스, 업데이트 및 추세 분석
  • 포괄적인 경쟁자 추적을 위한 벤치마크 분석의 힘 활용
데모 요청

목차

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF THE EUROPE LIVER CANCER DIAGNOSTICS MARKET

1.4 CURRENCY AND PRICING

1.5 LIMITATIONS

1.6 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 DBMR TRIPOD DATA VALIDATION MODEL

2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.6 MULTIVARIATE MODELLING

2.7 MARKET APPLICATION COVERAGE GRID

2.8 TEST TYPE LIFELINE CURVE

2.9 DBMR MARKET POSITION GRID

2.1 VENDOR SHARE ANALYSIS

2.11 SECONDARY SOURCES

2.12 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PESTLE ANALYSIS

4.2 PORTER ANALYSIS

4.3 EPIDEMIOLOGY

5 EUROPE LIVER CANCER DIAGNOSTICS MARKET, REGULATIONS

6 INDUSTRY INSIGHTS

7 MARKET OVERVIEW

7.1 DRIVERS

7.1.1 UNMET NEED FOR NON-INVASIVE, ACCURATE, AND RELIABLE DIAGNOSTIC TESTS FOR EARLIER CANCER DETECTION

7.1.2 INCREASING EARLY DIAGNOSIS OF LIVER CANCER

7.1.3 INCREASING CASES OF LIVER CANCER

7.1.4 RISE IN DIAGNOSTIC PRODUCT APPROVALS

7.2 RESTRAINTS

7.2.1 BARRIERS TO LIVER CANCER DIAGNOSIS AND POOR PROGNOSIS

7.2.2 HIGH FALSE-POSITIVES AND POOR SENSITIVITY OF LIVER CANCER DIAGNOSIS

7.3 OPPORTUNITIES

7.3.1 INCREASING AWARENESS TOWARDS LIVER CANCER

7.3.2 GOVERNMENT INITIATIVES TOWARD LIVER CANCER DIAGNOSTICS

7.3.3 GROWING DEMAND FOR BETTER QUALITY HEALTHCARE

7.4 CHALLENGES

7.4.1 STRICT REGULATIONS FOR THE APPROVAL OF LIVER CANCER DIAGNOSTIC PRODUCTS

7.4.2 LACK OF SKILLED AND CERTIFIED EXPERTISE

8 EUROPE LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE

8.1 OVERVIEW

8.2 IMAGING TEST

8.2.1 MAGNETIC RESONANCE IMAGING (MRI)

8.2.1.1 MR ANGIOGRAPHY (MRA)

8.2.1.2 MR CHOLANGIOPANCREATOGRAPHY

8.2.2 COMPUTED TOMOGRAPHY

8.2.3 POSITRON EMISSION TOMOGRAPHY

8.2.4 ULTRASOUND

8.2.5 OTHERS

8.3 GENOMIC TEST

8.4 BIOPSY

8.4.1 FINE NEEDLE ASPIRATION BIOPSY

8.4.2 CORE NEEDLE BIOPSY

8.4.3 LAPAROSCOPY

8.5 OTHERS

9 EUROPE LIVER CANCER DIAGNOSTICS MARKET, BY CANCER STAGE

9.1 OVERVIEW

9.2 STAGE III

9.3 STAGE II

9.4 STAGE IV

9.5 STAGE I

9.6 STAGE 0

10 EUROPE LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE

10.1 OVERVIEW

10.2 SECONDARY LIVER CANCER

10.2.1 HEMANGIOMA

10.2.2 HEPATIC ADENOMA

10.2.3 FOCAL NODULAR HYPERPLASIA

10.3 PRIMARY LIVER CANCER

10.3.1 HEPATOCELLULAR CARCINOMA (HCC)

10.3.2 INTRAHEPATIC CHOLANGIOCARCINOMA (BILE DUCT CANCER)

10.3.3 ANGIOSARCOMA HEMANGIOSARCOMA

10.3.4 HEPATOBLASTOMA

11 EUROPE LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT

11.1 OVERVIEW

11.2 PLATFORM BASED PRODUCTS

11.2.1 NEXT GENERATION SEQUENCING

11.2.2 MICROARRAYS

11.2.3 PCR

11.2.4 OTHERS

11.3 INSTRUMENT BASED PRODUCTS

11.3.1 IMAGING

11.3.2 BIOPSY

11.4 KITS AND REAGENTS

11.4.1 ELISA TEST KITS

11.4.2 CASSETTE TEST KITS

11.4.3 OTHERS

11.5 OTHER CONSUMABLES

12 EUROPE LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION

12.1 OVERVIEW

12.2 SCREENING

12.2.1 PLATFORM BASED PRODUCTS

12.2.2 INSTRUMENT BASED PRODUCTS

12.2.3 KITS AND REAGENTS

12.2.4 OTHER CONSUMABLES

12.3 DIAGNOSTIC AND PREDICTIVE

12.3.1 PLATFORM BASED PRODUCTS

12.3.2 INSTRUMENT BASED PRODUCTS

12.3.3 KITS AND REAGENTS

12.3.4 OTHER CONSUMABLES

12.4 PROGNOSTIC

12.4.1 PLATFORM BASED PRODUCTS

12.4.2 INSTRUMENT BASED PRODUCTS

12.4.3 KITS AND REAGENTS

12.4.4 OTHER CONSUMABLES

12.5 RESEARCH

12.5.1 PLATFORM BASED PRODUCTS

12.5.2 INSTRUMENT BASED PRODUCTS

12.5.3 KITS AND REAGENTS

12.5.4 OTHER CONSUMABLES

13 EUROPE LIVER CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY

13.1 OVERVIEW

13.2 FLUORESCENT IN SITU HYBRIDIZATION

13.3 NEXT GENERATION SEQUENCING

13.4 FLUORIMMUNOASSAY

13.5 COMPARATIVE GENOMIC HYBRIDIZATION

13.6 IMMUNOHISTOCHEMICAL

13.7 OTHERS

14 EUROPE LIVER CANCER DIAGNOSTICS MARKET, BY GENDER

14.1 OVERVIEW

14.2 MALE

14.3 FEMALE

15 EUROPE LIVER CANCER DIAGNOSTICS MARKET, BY END USER

15.1 OVERVIEW

15.2 HOSPITALS

15.3 DIAGNOSTIC CENTERS

15.4 CANCER RESEARCH CENTERS

15.5 AMBULATORY SURGICAL CENTERS

15.6 ACADEMIC INSTITUTES

15.7 OTHERS

16 EUROPE LIVER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL

16.1 OVERVIEW

16.2 DIRECT TENDER

16.3 RETAIL SALES

16.4 OTHERS

17 EUROPE LIVER CANCER DIAGNOSTICS MARKET, BY REGION

17.1 EUROPE

17.1.1 GERMANY

17.1.2 FRANCE

17.1.3 RUSSIA

17.1.4 ITALY

17.1.5 U.K.

17.1.6 SPAIN

17.1.7 TURKEY

17.1.8 NETHERLANDS

17.1.9 BELGIUM

17.1.10 SWITZERLAND

17.1.11 REST OF EUROPE

18 EUROPE LIVER CANCER DIAGNOSTICS MARKET, COMPANY LANDSCAPE

18.1 COMPANY SHARE ANALYSIS: EUROPE

19 SWOT ANALYSIS

20 COMPANY PROFILE

20.1 F. HOFFMANN-LA ROCHE LTD.

20.1.1 COMPANY SNAPSHOT

20.1.2 REVENUE ANALYSIS

20.1.3 COMPANY SHARE ANALYSIS

20.1.4 PRODUCT PORTFOLIO

20.1.5 RECENT DEVELOPMENT

20.2 KONINLIJKE PHILIPS N.V.

20.2.1 COMPANY SNAPSHOT

20.2.2 REVENUE ANALYSIS

20.2.3 COMPANY SHARE ANALYSIS

20.2.4 PRODUCT PORTFOLIO

20.2.5 RECENT DEVELOPMENT

20.3 THERMO FISHER SCIENTIFIC INC.

20.3.1 COMPANY SNAPSHOT

20.3.2 REVENUE ANALYSIS

20.3.3 COMPANY SHARE ANALYSIS

20.3.4 PRODUCT PORTFOLIO

20.3.5 RECENT DEVELOPMENT

20.4 BD

20.4.1 COMPANY SNAPSHOT

20.4.2 REVENUE ANALYSIS

20.4.3 COMPANY SHARE ANALYSIS

20.4.4 PRODUCT PORTFOLIO

20.4.5 RECENT DEVELOPMENTS

20.5 SIEMENS HEALTHCARE GMBH

20.5.1 COMPANY SNAPSHOT

20.5.2 REVENUE ANALYSIS

20.5.3 COMPANY SHARE ANALYSIS

20.5.4 PRODUCT PORTFOLIO

20.5.5 RECENT DEVELOPMENT

20.6 AGILENT TECHNOLOGIES, INC.

20.6.1 COMPANY SNAPSHOT

20.6.2 REVENUE ANALYSIS

20.6.3 PRODUCT PORTFOLIO

20.6.4 RECENT DEVELOPMENTS

20.7 ABK BIOMEDICAL INC.

20.7.1 COMPANY SNAPSHOT

20.7.2 PRODUCT PORTFOLIO

20.7.3 RECENT DEVELOPMENT

20.8 AB SCIEX PTE LTD. (SUBSIDIARY OF DANAHER.)

20.8.1 COMPANY SNAPSHOT

20.8.2 REVENUE ANALYSIS

20.8.3 PRODUCT PORTFOLIO

20.8.4 RECENT DEVELOPMENT

20.9 ALTOGEN BIOSYSTEMS

20.9.1 COMPANY SNAPSHOT

20.9.2 PRODUCT PORTFOLIO

20.9.3 RECENT DEVELOPMENT

20.1 BIOCEPT, INC.

20.10.1 COMPANY SNAPSHOT

20.10.2 REVENUE ANALYSIS

20.10.3 PRODUCT PORTFOLIO

20.10.4 RECENT DEVELOPMENT

20.11 BODITECH MED INC.

20.11.1 COMPANY SNAPSHOT

20.11.2 PRODUCT PORTFOLIO

20.11.3 RECENT DEVELOPMENTS

20.12 DIAGNOSTIC BIOSYSTEMS INC.

20.12.1 COMPANY SNAPSHOT

20.12.2 PRODUCT PORTFOLIO

20.12.3 RECENT DEVELOPMENT

20.13 DIAZYME LABORATORIES, INC.

20.13.1 COMPANY SNAPSHOT

20.13.2 PRODUCT PORTFOLIO

20.13.3 RECENT DEVELOPMENT

20.14 ELABSCIENCE BIOTECHNOLOGY INC.

20.14.1 COMPANY SNAPSHOT

20.14.2 PRODUCT PORTFOLIO

20.14.3 RECENT DEVELOPMENT

20.15 EPIGENOMICS AG

20.15.1 COMPANY SNAPSHOT

20.15.2 REVENUE ANALYSIS

20.15.3 PRODUCT PORTFOLIO

20.15.4 RECENT DEVELOPMENT

20.16 FUJIFILM CORPORATION

20.16.1 COMPANY SNAPSHOT

20.16.2 REVENUE ANALYSIS

20.16.3 PRODUCT PORTFOLIO

20.16.4 RECENT DEVELOPMENT

20.17 FUJIREBIO

20.17.1 COMPANY SNAPSHOT

20.17.2 PRODUCT PORTFOLIO

20.17.3 RECENT DEVELOPMENTS

20.18 HIPRO BIOTECHNOLOGY CO., LTD.

20.18.1 COMPANY SNAPSHOT

20.18.2 PRODUCT PORTFOLIO

20.18.3 RECENT DEVELOPMENT

20.19 ILLUMINA, INC.

20.19.1 COMPANY SNAPSHOT

20.19.2 REVENUE ANALYSIS

20.19.3 PRODUCT PORTFOLIO

20.19.4 RECENT DEVELOPMENTS

20.2 MOLGEN

20.20.1 COMPANY SNAPSHOT

20.20.2 PRODUCT PORTFOLIO

20.20.3 RECENT DEVELOPMENT

20.21 QIAGEN

20.21.1 COMPANY SNAPSHOT

20.21.2 REVENUE ANALYSIS

20.21.3 PRODUCT PORTFOLIO

20.21.4 RECENT DEVELOPMENT

20.22 Q-LINE BIOTECH PVT LTD.

20.22.1 COMPANY SNAPSHOT

20.22.2 PRODUCT PORTFOLIO

20.22.3 RECENT DEVELOPMENT

20.23 SYSMEX CORPORATION

20.23.1 COMPANY SNAPSHOT

20.23.2 REVENUE ANALYSIS

20.23.3 PRODUCT PORTFOLIO

20.23.4 RECENT DEVELOPMENT

20.24 TEBUBIO

20.24.1 COMPANY SNAPSHOT

20.24.2 PRODUCT PORTFOLIO

20.24.3 RECENT DEVELOPMENT

20.25 TOSOH INDIA PVT. LTD.

20.25.1 COMPANY SNAPSHOT

20.25.2 PRODUCT PORTFOLIO

20.25.3 RECENT DEVELOPMENT

21 QUESTIONNAIRE

22 RELATED REPORTS

표 목록

TABLE 1 DIFFERENT TYPES OF CANCER NON-INVASIVE SCREENING TESTS FOR DIFFERENT TYPES OF CANCERS

TABLE 2 LIVER CANCER RATES

TABLE 3 APPROVED DIAGNOSTICS OF LIVER CANCER

TABLE 4 EUROPE LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 5 EUROPE IMAGING IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 6 EUROPE IMAGING TEST IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 7 EUROPE MAGNETIC RESONANCE IMAGING (MRI) IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 8 EUROPE GENETIC TEST IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 9 EUROPE BIOPSY IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 10 EUROPE BIOPSY IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 11 EUROPE OTHERS IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 12 EUROPE LIVER CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)

TABLE 13 EUROPE STAGE III IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 14 EUROPE STAGE II IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 15 EUROPE STAGE IV IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 16 EUROPE STAGE I IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 17 EUROPE STAGE 0 IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 18 EUROPE LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 19 EUROPE SECONDARY LIVER CANCER IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 20 EUROPE RENAL CELL CARCINOMA IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 21 EUROPE CLEAR CELL RENAL CELL CARCINOMA IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 22 EUROPE CLEAR CELL RENAL CELL CARCINOMA IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 23 EUROPE LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 24 EUROPE PLATFORM BASED PRODUCTS IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 25 EUROPE PLATFORM BASED PRODUCTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 26 EUROPE INSTRUMENT BASED PRODUCTS IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 27 EUROPE INSTRUMENT BASED PRODUCTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 28 EUROPE KITS AND REAGENTS IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 29 EUROPE KITS AND REAGENTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 30 EUROPE OTHER CONSUMABLES IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 31 EUROPE LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 32 EUROPE SCREENING IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 33 EUROPE SCREENING IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 34 EUROPE DIAGNOSTIC AND PREDICTIVE IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 35 EUROPE DIAGNOSTIC AND PREDICTIVE IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 36 EUROPE PROGNOSTIC IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 37 EUROPE PROGNOSTIC IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 38 EUROPE RESEARCH IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 39 EUROPE RESEARCH IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 40 EUROPE LIVER CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 41 EUROPE FLUORESCENT IN SITU HYBRIDIZATION IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 42 EUROPE NEXT GENERATION SEQUENCING IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 43 EUROPE FLUORIMMUNOASSAY IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 44 EUROPE COMPARATIVE GENOMIC HYBRIDIZATION IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 45 EUROPE IMMUNOHISTOCHEMICAL IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 46 EUROPE OTHERS IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 47 EUROPE LIVER CANCER DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 48 EUROPE MALE IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 49 EUROPE FEMALE IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 50 EUROPE LIVER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 51 EUROPE HOSPITALS IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 52 EUROPE DIAGNOSTIC CENTERS IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 53 EUROPE CANCER RESEARCH CENTERS IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 54 EUROPE AMBULATORY SURGICAL CENTERS IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 55 EUROPE ACADEMIC INSTITUTES IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 56 EUROPE OTHERS IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 57 EUROPE LIVER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 58 EUROPE DIRECT TENDER IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 59 EUROPE RETAIL SALES IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 60 EUROPE OTHERS IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 61 EUROPE LIVER CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2021-2030 (USD MILLION)

TABLE 62 EUROPE LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 63 EUROPE IMAGING TEST IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 64 EUROPE MAGNETIC RESONANCE IMAGING (MRI) IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE 2021-2030 (USD MILLION)

TABLE 65 EUROPE BIOPSY IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 66 EUROPE LIVER CANCER DIAGNOSTICS MARKET, BY CANCER STAGES, 2021-2030 (USD MILLION)

TABLE 67 EUROPE LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 68 EUROPE SECONDARY LIVER CANCER IN LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 69 EUROPE PRIMARY LIVER CANCER IN LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 70 EUROPE LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 71 EUROPE PLATFORM-BASED PRODUCTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 72 EUROPE INSTRUMENT-BASED PRODUCTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 73 EUROPE KITS & REAGENTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 74 EUROPE LIVER CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 75 EUROPE LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 76 EUROPE SCREENING IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 77 EUROPE DIAGNOSTIC AND PREDICTIVE IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 78 EUROPE PROGNOSTIC IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 79 EUROPE RESEARCH IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 80 EUROPE LIVER CANCER DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 81 EUROPE LIVER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 82 EUROPE LIVER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 83 GERMANY LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 84 GERMANY IMAGING TEST IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 85 GERMANY MAGNETIC RESONANCE IMAGING (MRI) IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE 2021-2030 (USD MILLION)

TABLE 86 GERMANY BIOPSY IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 87 GERMANY LIVER CANCER DIAGNOSTICS MARKET, BY CANCER STAGES, 2021-2030 (USD MILLION)

TABLE 88 GERMANY LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 89 GERMANY SECONDARY LIVER CANCER IN LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 90 GERMANY PRIMARY LIVER CANCER IN LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 91 GERMANY LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 92 GERMANY PLATFORM-BASED PRODUCTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 93 GERMANY INSTRUMENT-BASED PRODUCTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 94 GERMANY KITS & REAGENTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 95 GERMANY LIVER CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 96 GERMANY LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 97 GERMANY SCREENING IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 98 GERMANY DIAGNOSTIC AND PREDICTIVE IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 99 GERMANY PROGNOSTIC IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 100 GERMANY RESEARCH IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 101 GERMANY LIVER CANCER DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 102 GERMANY LIVER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 103 GERMANY LIVER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 104 FRANCE LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 105 FRANCE IMAGING TEST IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 106 FRANCE MAGNETIC RESONANCE IMAGING (MRI) IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE 2021-2030 (USD MILLION)

TABLE 107 FRANCE BIOPSY IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 108 FRANCE LIVER CANCER DIAGNOSTICS MARKET, BY CANCER STAGES, 2021-2030 (USD MILLION)

TABLE 109 FRANCE LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 110 FRANCE SECONDARY LIVER CANCER IN LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 111 FRANCE PRIMARY LIVER CANCER IN LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 112 FRANCE LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 113 FRANCE PLATFORM-BASED PRODUCTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 114 FRANCE INSTRUMENT-BASED PRODUCTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 115 FRANCE KITS & REAGENTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 116 FRANCE LIVER CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 117 FRANCE LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 118 FRANCE SCREENING IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 119 FRANCE DIAGNOSTIC AND PREDICTIVE IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 120 FRANCE PROGNOSTIC IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 121 FRANCE RESEARCH IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 122 FRANCE LIVER CANCER DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 123 FRANCE LIVER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 124 FRANCE LIVER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 125 RUSSIA LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 126 RUSSIA IMAGING TEST IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 127 RUSSIA MAGNETIC RESONANCE IMAGING (MRI) IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE 2021-2030 (USD MILLION)

TABLE 128 RUSSIA BIOPSY IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 129 RUSSIA LIVER CANCER DIAGNOSTICS MARKET, BY CANCER STAGES, 2021-2030 (USD MILLION)

TABLE 130 RUSSIA LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 131 RUSSIA SECONDARY LIVER CANCER IN LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 132 RUSSIA PRIMARY LIVER CANCER IN LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 133 RUSSIA LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 134 RUSSIA PLATFORM-BASED PRODUCTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 135 RUSSIA INSTRUMENT-BASED PRODUCTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 136 RUSSIA KITS & REAGENTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 137 RUSSIA LIVER CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 138 RUSSIA LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 139 RUSSIA SCREENING IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 140 RUSSIA DIAGNOSTIC AND PREDICTIVE IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 141 RUSSIA PROGNOSTIC IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 142 RUSSIA RESEARCH IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 143 RUSSIA LIVER CANCER DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 144 RUSSIA LIVER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 145 RUSSIA LIVER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 146 ITALY LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 147 ITALY IMAGING TEST IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 148 ITALY MAGNETIC RESONANCE IMAGING (MRI) IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE 2021-2030 (USD MILLION)

TABLE 149 ITALY BIOPSY IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 150 ITALY LIVER CANCER DIAGNOSTICS MARKET, BY CANCER STAGES, 2021-2030 (USD MILLION)

TABLE 151 ITALY LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 152 ITALY SECONDARY LIVER CANCER IN LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 153 ITALY PRIMARY LIVER CANCER IN LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 154 ITALY LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 155 ITALY PLATFORM-BASED PRODUCTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 156 ITALY INSTRUMENT-BASED PRODUCTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 157 ITALY KITS & REAGENTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 158 ITALY LIVER CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 159 ITALY LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 160 ITALY SCREENING IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 161 ITALY DIAGNOSTIC AND PREDICTIVE IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 162 ITALY PROGNOSTIC IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 163 ITALY RESEARCH IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 164 ITALY LIVER CANCER DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 165 ITALY LIVER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 166 ITALY LIVER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 167 U.K. LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 168 U.K. IMAGING TEST IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 169 U.K. MAGNETIC RESONANCE IMAGING (MRI) IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE 2021-2030 (USD MILLION)

TABLE 170 U.K. BIOPSY IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 171 U.K. LIVER CANCER DIAGNOSTICS MARKET, BY CANCER STAGES, 2021-2030 (USD MILLION)

TABLE 172 U.K. LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 173 U.K. SECONDARY LIVER CANCER IN LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 174 U.K. PRIMARY LIVER CANCER IN LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 175 U.K. LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 176 U.K. PLATFORM-BASED PRODUCTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 177 U.K. INSTRUMENT-BASED PRODUCTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 178 U.K. KITS & REAGENTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 179 U.K. LIVER CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 180 U.K. LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 181 U.K. SCREENING IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 182 U.K. DIAGNOSTIC AND PREDICTIVE IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 183 U.K. PROGNOSTIC IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 184 U.K. RESEARCH IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 185 U.K. LIVER CANCER DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 186 U.K. LIVER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 187 U.K. LIVER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 188 SPAIN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 189 SPAIN IMAGING TEST IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 190 SPAIN MAGNETIC RESONANCE IMAGING (MRI) IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE 2021-2030 (USD MILLION)

TABLE 191 SPAIN BIOPSY IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 192 SPAIN LIVER CANCER DIAGNOSTICS MARKET, BY CANCER STAGES, 2021-2030 (USD MILLION)

TABLE 193 SPAIN LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 194 SPAIN SECONDARY LIVER CANCER IN LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 195 SPAIN PRIMARY LIVER CANCER IN LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 196 SPAIN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 197 SPAIN PLATFORM-BASED PRODUCTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 198 SPAIN INSTRUMENT-BASED PRODUCTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 199 SPAIN KITS & REAGENTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 200 SPAIN LIVER CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 201 SPAIN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 202 SPAIN SCREENING IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 203 SPAIN DIAGNOSTIC AND PREDICTIVE IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 204 SPAIN PROGNOSTIC IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 205 SPAIN RESEARCH IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 206 SPAIN LIVER CANCER DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 207 SPAIN LIVER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 208 SPAIN LIVER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 209 TURKEY LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 210 TURKEY IMAGING TEST IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 211 TURKEY MAGNETIC RESONANCE IMAGING (MRI) IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE 2021-2030 (USD MILLION)

TABLE 212 TURKEY BIOPSY IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 213 TURKEY LIVER CANCER DIAGNOSTICS MARKET, BY CANCER STAGES, 2021-2030 (USD MILLION)

TABLE 214 TURKEY LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 215 TURKEY SECONDARY LIVER CANCER IN LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 216 TURKEY PRIMARY LIVER CANCER IN LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 217 TURKEY LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 218 TURKEY PLATFORM-BASED PRODUCTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 219 TURKEY INSTRUMENT-BASED PRODUCTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 220 TURKEY KITS & REAGENTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 221 TURKEY LIVER CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 222 TURKEY LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 223 TURKEY SCREENING IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 224 TURKEY DIAGNOSTIC AND PREDICTIVE IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 225 TURKEY PROGNOSTIC IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 226 TURKEY RESEARCH IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 227 TURKEY LIVER CANCER DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 228 TURKEY LIVER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 229 TURKEY LIVER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 230 NETHERLANDS LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 231 NETHERLANDS IMAGING TEST IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 232 NETHERLANDS MAGNETIC RESONANCE IMAGING (MRI) IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE 2021-2030 (USD MILLION)

TABLE 233 NETHERLANDS BIOPSY IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 234 NETHERLANDS LIVER CANCER DIAGNOSTICS MARKET, BY CANCER STAGES, 2021-2030 (USD MILLION)

TABLE 235 NETHERLANDS LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 236 NETHERLANDS SECONDARY LIVER CANCER IN LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 237 NETHERLANDS PRIMARY LIVER CANCER IN LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 238 NETHERLANDS LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 239 NETHERLANDS PLATFORM-BASED PRODUCTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 240 NETHERLANDS INSTRUMENT-BASED PRODUCTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 241 NETHERLANDS KITS & REAGENTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 242 NETHERLANDS LIVER CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 243 NETHERLANDS LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 244 NETHERLANDS SCREENING IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 245 NETHERLANDS DIAGNOSTIC AND PREDICTIVE IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 246 NETHERLANDS PROGNOSTIC IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 247 NETHERLANDS RESEARCH IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 248 NETHERLANDS LIVER CANCER DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 249 NETHERLANDS LIVER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 250 NETHERLANDS LIVER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 251 BELGIUM LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 252 BELGIUM IMAGING TEST IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 253 BELGIUM MAGNETIC RESONANCE IMAGING (MRI) IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE 2021-2030 (USD MILLION)

TABLE 254 BELGIUM BIOPSY IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 255 BELGIUM LIVER CANCER DIAGNOSTICS MARKET, BY CANCER STAGES, 2021-2030 (USD MILLION)

TABLE 256 BELGIUM LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 257 BELGIUM SECONDARY LIVER CANCER IN LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 258 BELGIUM PRIMARY LIVER CANCER IN LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 259 BELGIUM LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 260 BELGIUM PLATFORM-BASED PRODUCTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 261 BELGIUM INSTRUMENT-BASED PRODUCTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 262 BELGIUM KITS & REAGENTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 263 BELGIUM LIVER CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 264 BELGIUM LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 265 BELGIUM SCREENING IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 266 BELGIUM DIAGNOSTIC AND PREDICTIVE IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 267 BELGIUM PROGNOSTIC IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 268 BELGIUM RESEARCH IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 269 BELGIUM LIVER CANCER DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 270 BELGIUM LIVER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 271 BELGIUM LIVER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 272 SWITZERLAND LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 273 SWITZERLAND IMAGING TEST IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 274 SWITZERLAND MAGNETIC RESONANCE IMAGING (MRI) IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE 2021-2030 (USD MILLION)

TABLE 275 SWITZERLAND BIOPSY IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 276 SWITZERLAND LIVER CANCER DIAGNOSTICS MARKET, BY CANCER STAGES, 2021-2030 (USD MILLION)

TABLE 277 SWITZERLAND LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 278 SWITZERLAND SECONDARY LIVER CANCER IN LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 279 SWITZERLAND PRIMARY LIVER CANCER IN LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 280 SWITZERLAND LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 281 SWITZERLAND PLATFORM-BASED PRODUCTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 282 SWITZERLAND INSTRUMENT-BASED PRODUCTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 283 SWITZERLAND KITS & REAGENTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 284 SWITZERLAND LIVER CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 285 SWITZERLAND LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 286 SWITZERLAND SCREENING IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 287 SWITZERLAND DIAGNOSTIC AND PREDICTIVE IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 288 SWITZERLAND PROGNOSTIC IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 289 SWITZERLAND RESEARCH IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 290 SWITZERLAND LIVER CANCER DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 291 SWITZERLAND LIVER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 292 SWITZERLAND LIVER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 293 REST OF EUROPE LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

그림 목록

FIGURE 1 EUROPE LIVER CANCER DIAGNOSTICS MARKET: SEGMENTATION

FIGURE 2 EUROPE LIVER CANCER DIAGNOSTICS MARKET: DATA TRIANGULATION

FIGURE 3 EUROPE LIVER CANCER DIAGNOSTICS MARKET: DROC ANALYSIS

FIGURE 4 EUROPE LIVER CANCER DIAGNOSTICS MARKET: EUROPE VS REGIONAL MARKET ANALYSIS

FIGURE 5 EUROPE LIVER CANCER DIAGNOSTICS MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 EUROPE LIVER CANCER DIAGNOSTICS MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 EUROPE LIVER CANCER DIAGNOSTICS MARKET: MARKET APPLICATION COVERAGE GRID

FIGURE 8 EUROPE LIVER CANCER DIAGNOSTICS MARKET: DBMR MARKET POSITION GRID

FIGURE 9 EUROPE LIVER CANCER DIAGNOSTICS MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 EUROPE LIVER CANCER DIAGNOSTICS MARKET: SEGMENTATION

FIGURE 11 GROWING AWARENESS OF LIVER CANCER AND INCREASING HEALTHCARE EXPENDITURE ARE EXPECTED TO DRIVE THE GROWTH OF THE EUROPE LIVER CANCER DIAGNOSTICS MARKET FROM 2023 TO 2030

FIGURE 12 THE IMAGING TEST SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE LIVER CANCER DIAGNOSTICS MARKET IN 2023 & 2030

FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE EUROPE LIVER CANCER DIAGNOSTICS MARKET

FIGURE 14 THE EUROPE MORTALITY RATE DUE TO CANCER

FIGURE 15 INCREASING EUROPE CANCER RATE IN 2020

FIGURE 16 BARRIERS TO EARLY CANCER DIAGNOSIS AND TREATMENT

FIGURE 17 EUROPE LIVER CANCER DIAGNOSTICS MARKET: BY TEST TYPE, 2022

FIGURE 18 EUROPE LIVER CANCER DIAGNOSTICS MARKET: BY TEST TYPE, 2023-2030 (USD MILLION)

FIGURE 19 EUROPE LIVER CANCER DIAGNOSTICS MARKET: BY TEST TYPE, CAGR (2023-2030)

FIGURE 20 EUROPE LIVER CANCER DIAGNOSTICS MARKET: BY TEST TYPE, LIFELINE CURVE

FIGURE 21 EUROPE LIVER CANCER DIAGNOSTICS MARKET: BY CANCER STAGE, 2022

FIGURE 22 EUROPE LIVER CANCER DIAGNOSTICS MARKET: BY CANCER STAGE, 2023-2030 (USD MILLION)

FIGURE 23 EUROPE LIVER CANCER DIAGNOSTICS MARKET: BY CANCER STAGE, CAGR (2023-2030)

FIGURE 24 EUROPE LIVER CANCER DIAGNOSTICS MARKET: BY CANCER STAGE, LIFELINE CURVE

FIGURE 25 EUROPE LIVER CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, 2022

FIGURE 26 EUROPE LIVER CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, 2023-2030 (USD MILLION)

FIGURE 27 EUROPE LIVER CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, CAGR (2023-2030)

FIGURE 28 EUROPE LIVER CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, LIFELINE CURVE

FIGURE 29 EUROPE LIVER CANCER DIAGNOSTICS MARKET: BY PRODUCT, 2022

FIGURE 30 EUROPE LIVER CANCER DIAGNOSTICS MARKET: BY PRODUCT, 2023-2030 (USD MILLION)

FIGURE 31 EUROPE LIVER CANCER DIAGNOSTICS MARKET: BY PRODUCT, CAGR (2023-2030)

FIGURE 32 EUROPE LIVER CANCER DIAGNOSTICS MARKET: BY PRODUCT, LIFELINE CURVE

FIGURE 33 EUROPE LIVER CANCER DIAGNOSTICS MARKET: BY APPLICATION, 2022

FIGURE 34 EUROPE LIVER CANCER DIAGNOSTICS MARKET: BY APPLICATION, 2023-2030 (USD MILLION)

FIGURE 35 EUROPE LIVER CANCER DIAGNOSTICS MARKET: BY APPLICATION, CAGR (2023-2030)

FIGURE 36 EUROPE LIVER CANCER DIAGNOSTICS MARKET: BY APPLICATION, LIFELINE CURVE

FIGURE 37 EUROPE LIVER CANCER DIAGNOSTICS MARKET: BY TECHNOLOGY, 2022

FIGURE 38 EUROPE LIVER CANCER DIAGNOSTICS MARKET: BY TECHNOLOGY, 2023-2030 (USD MILLION)

FIGURE 39 EUROPE LIVER CANCER DIAGNOSTICS MARKET: BY TECHNOLOGY, CAGR (2023-2030)

FIGURE 40 EUROPE LIVER CANCER DIAGNOSTICS MARKET: BY TECHNOLOGY, LIFELINE CURVE

FIGURE 41 EUROPE LIVER CANCER DIAGNOSTICS MARKET: BY GENDER, 2022

FIGURE 42 EUROPE LIVER CANCER DIAGNOSTICS MARKET: BY GENDER, 2023-2030 (USD MILLION)

FIGURE 43 EUROPE LIVER CANCER DIAGNOSTICS MARKET: BY GENDER, CAGR (2023-2030)

FIGURE 44 EUROPE LIVER CANCER DIAGNOSTICS MARKET: BY GENDER, LIFELINE CURVE

FIGURE 45 EUROPE LIVER CANCER DIAGNOSTICS MARKET: BY END USER, 2022

FIGURE 46 EUROPE LIVER CANCER DIAGNOSTICS MARKET: BY END USER, 2023-2030 (USD MILLION)

FIGURE 47 EUROPE LIVER CANCER DIAGNOSTICS MARKET: BY END USER, CAGR (2023-2030)

FIGURE 48 EUROPE LIVER CANCER DIAGNOSTICS MARKET: BY END USER, LIFELINE CURVE

FIGURE 49 EUROPE LIVER CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2022

FIGURE 50 EUROPE LIVER CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)

FIGURE 51 EUROPE LIVER CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)

FIGURE 52 EUROPE LIVER CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 53 EUROPE LIVER CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022)

FIGURE 54 EUROPE LIVER CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022)

FIGURE 55 EUROPE LIVER CANCER DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030)

FIGURE 56 EUROPE LIVER CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030)

FIGURE 57 EUROPE LIVER CANCER DIAGNOSTICS MARKET: PRODUCT TYPE (2023-2030)

FIGURE 58 EUROPE LIVER CANCER DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%)

자세한 정보 보기 Right Arrow

연구 방법론

데이터 수집 및 기준 연도 분석은 대규모 샘플 크기의 데이터 수집 모듈을 사용하여 수행됩니다. 이 단계에는 다양한 소스와 전략을 통해 시장 정보 또는 관련 데이터를 얻는 것이 포함됩니다. 여기에는 과거에 수집한 모든 데이터를 미리 검토하고 계획하는 것이 포함됩니다. 또한 다양한 정보 소스에서 발견되는 정보 불일치를 검토하는 것도 포함됩니다. 시장 데이터는 시장 통계 및 일관된 모델을 사용하여 분석하고 추정합니다. 또한 시장 점유율 분석 및 주요 추세 분석은 시장 보고서의 주요 성공 요인입니다. 자세한 내용은 분석가에게 전화를 요청하거나 문의 사항을 드롭하세요.

DBMR 연구팀에서 사용하는 주요 연구 방법론은 데이터 마이닝, 시장에 대한 데이터 변수의 영향 분석 및 주요(산업 전문가) 검증을 포함하는 데이터 삼각 측량입니다. 데이터 모델에는 공급업체 포지셔닝 그리드, 시장 타임라인 분석, 시장 개요 및 가이드, 회사 포지셔닝 그리드, 특허 분석, 가격 분석, 회사 시장 점유율 분석, 측정 기준, 글로벌 대 지역 및 공급업체 점유율 분석이 포함됩니다. 연구 방법론에 대해 자세히 알아보려면 문의를 통해 업계 전문가에게 문의하세요.

사용자 정의 가능

Data Bridge Market Research는 고급 형성 연구 분야의 선두 주자입니다. 저희는 기존 및 신규 고객에게 목표에 맞는 데이터와 분석을 제공하는 데 자부심을 느낍니다. 보고서는 추가 국가에 대한 시장 이해(국가 목록 요청), 임상 시험 결과 데이터, 문헌 검토, 재생 시장 및 제품 기반 분석을 포함하도록 사용자 정의할 수 있습니다. 기술 기반 분석에서 시장 포트폴리오 전략에 이르기까지 타겟 경쟁업체의 시장 분석을 분석할 수 있습니다. 귀하가 원하는 형식과 데이터 스타일로 필요한 만큼 많은 경쟁자를 추가할 수 있습니다. 저희 분석가 팀은 또한 원시 엑셀 파일 피벗 테이블(팩트북)로 데이터를 제공하거나 보고서에서 사용 가능한 데이터 세트에서 프레젠테이션을 만드는 데 도움을 줄 수 있습니다.

자주 묻는 질문

The Europe Liver Cancer Diagnostics Market is projected to grow at a CAGR of 6.0% during the forecast period by 2030.
The future market value of the Europe Liver Cancer Diagnostics Market is expected to reach USD 2,533.55 Million by 2030.
The major players in the Europe Liver Cancer Diagnostics Market are Siemens Healthcare GmbH (Germany), Koninklijke Philips N.V.(Netherland), Agilent Technologies, Inc. (U.S.), Illumina, Inc. (U.S.), Epigenomics AG (Germany), Tebubio, Thermo Fisher Scientific Inc. (U.S.), etc.
The countries covered in the Europe Liver Cancer Diagnostics Market are Germany, France, U.K., Italy, Russia, Spain, Netherlands, Switzerland, Norway, Poland, Sweden, Belgium, Turkey, Denmark, Finland, and the Rest of Europe.